News

Alpheus Medical Raises $52M in Series B Round to Advance Groundbreaking Glioblastoma Therapy Funding will support a randomized Phase 2B study of the novel sonodynamic therapy in patients with newly diagnosed glioblastoma Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the closing of an oversubscribed $52 million Series B financing round. The funds will support […] May 15, 2025

Alpheus Medical Publishes Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the publication of a study in the Journal of Neuro-Oncology showcasing its proprietary SDT treatment in three patients with newly diagnosed glioblastomas that were not candidates for gross total tumor resection. The study reported no adverse […] February 26, 2025

MimiVax Announces Positive Interim Analysis in Ongoing SurVaxM Clinical Trial -Ongoing clinical trial of SurVaxM in glioblastoma [SURVIVE] has successfully progressed following an interim analysis of trial data -The clinical trial is designed to evaluate the safety, efficacy, and overall benefit of SurVaxM in patients with newly diagnosed glioblastoma who receive standard-of-care treatment combined with SurVaxM -The fully enrolled Phase 2b SURVIVE study will continue as planned […] February 13, 2025

Cordance Medical and EXACT Therapeutics Announce Early Encouraging Data in Brain Cancer Mice Model Cordance Medical, a pioneer in non-invasive medical technologies for brain disease treatment, and EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, are pleased to announce initial positive results indicating more than a doubling (+127-145%) of the uptake of a radiopharmaceutical in brain tumors of mice inoculated with glioblastoma cancer cells, one of the […] January 30, 2025

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas  –The results from their first-in-human study demonstrated that median overall survival was doubled and progression-free survival improved 3-fold –The Company’s novel sonodynamic therapy platform selectively targets and destroys cancer cells in the brain while preserving healthy tissue  Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body […] November 26, 2024